Clinical Trial

A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of Serplulimab Injection (HLX10, a Recombinant Anti-PD-1 Antibody) and HLX04 (a Biosimilar to Bevacizumab) With or Without HLX53 (an Anti-TIGIT Fc Fusion Protein) in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-01; most recent amendment 2024-12-15.
Status change: Not Yet Recruiting → Recruiting 2024-12-15
Trial Details
NCT Number NCT06349980
Lead Sponsor Shanghai Henlius Biotech
Conditions Carcinoma, Hepatocellular
Enrollment 117 participants
Start Date 2024-08-05
Primary Completion 2027-02-10 (estimated)
Study Completion 2027-02-10 (estimated)
Updated on ClinicalTrials.gov 2024-12-18